Mobile App

Google Play Apple Store
Talking Prostate Cancer: Homologous Recombination Repair Gene Mutation Testing in Metastatic Prostate Cancer
The most recent guidelines recommend germline and/or somatic homologous recombination repair (HRR) gene panel testing to identify patients with metastatic prostate cancer that can benefit from poly-ADP ribose polymerase (PARP) inhibitors. However, HRR gene mutation (HRRm) testing rates are low and as a result, many patients with metastatic prostate cancer are unable to avail of these new therapies that have the potential to improve survival outcomes. This has been attributed to limited awareness about testing, inadequate sample, challenges with reimbursement, lack of patient counseling, and costs. Improving clinician and allied healthcare professional familiarity with HRRm testing guidelines and implementation recommendations, is therefore of utmost importance.

In these Mini Modules, Drs. Andrew Armstrong and Tanya Dorff use a discussion and case-based format to clarify the rationale for HRRm testing in metastatic prostate cancer and ensure better integration of the latest guidelines for testing by addressing barriers. The overall aim is to enable appropriate utilization of HRRm testing to ultimately improve outcomes among patients.
Review the activity and claim AMA/ABS/ANCC credit/contact hour after completion of a brief pretest and posttest/evaluation.

Andrew Armstrong, MD, ScM, FACP Andrew Armstrong, MD, ScM, FACP
Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Duke University

Tanya Dorff, MD Tanya Dorff, MD
Professor of Medicine
City of Hope

Supported by an independent educational grant from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Launch Date: May 28, 2024
Release Date: May 28, 2024
Expiration Date: April 30, 2025

Mini Module


Change Settings